RAMM Pharma is a leader in the research and development of cannabinoid pharmaceutical formulations. The company has developed Epifractán™ - Latin America's first registered cannabinoid pharmaceutical drug. RAMM Pharma has since expanded its array of formulations and products, including approved and registered products that are sold commercially. It also has a pipeline of new products in various stages of approval and development.